Among patients with pulmonary arterial hypertension treated with 72-week seralutinib, those deemed responders had more improved measures, according to a poster presented at the Pulmonary Vascular ...
Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...
Advanced therapies, medicines bring new hope for pulmonary hypertension patients: Dr Manisha Mendiratta: Shardul Nautiyal, Mumbai Saturday, February 8, 2025, 08:00 Hrs [IST] Dr Ma ...
Seropositive rheumatoid arthritis may be protective against the development of PAH, based on results of Mendelian randomization analyses.
Safety of a Potential New Treatment to Manage Complications from Sickle Cell Disease Apr. 11, 2024 — A drug approved to treat pulmonary arterial hypertension may be effective at managing ...
Women are more likely to have pulmonary arterial hypertension, but men tend to have worse outcomes and worse treatment responses.
Lungpacer Medical today announced positive results from a Phase 1 clinical study evaluating its neurostimulation technology ...
SAN DIEGO, February 07, 2025--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback